M&A Shuffle INFOGRAPHIC: Is Valeant target Allergan buying Salix?
This article was originally published in Scrip
Executive Summary
Allergan's divulging no details, but the company reportedly is in talks to buy Salix Pharmaceuticals in an effort to thwart an unwanted $50bn-plus buyout from Valeant Pharmaceuticals while at the same time rejecting an offer from Actavis, which supposedly is a new target for tax inversion-hungry Pfizer.